CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

Blood

Volumn 100, Issue 6, 2002, Pages 2132-2137

  Scheibenbogen, Carmen ^a   Letsch, Anne ^a   Thiel, Eckhard ^a   Schmittel, Alexander ^a   Mailaender, Volker ^a   Baerwolf, Steffi ^a   Nagorsen, Dirk ^a   Keilholz, Ulrich ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD3 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GENE PRODUCT; HLA A ANTIGEN; MYELOBLASTIN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; NEPHROBLASTOMA; PRIORITY JOURNAL;

EID: 0037105370     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0163     Document Type: Article

References (34)

1. Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia
2. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia
3. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells
4. Donor leukocyte transfusions for leukemic relapse
5. IL-2 and leukemia
6. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse
7. Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: Implications for adoptive immunotherapy
8. Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias
9. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia
10. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells
11. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells
12. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells
13. Cancer immunotherapy targeting Wilms' tumor gene WT1 product
14. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination
15. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
16. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product
17. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1
18. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
19. Proteinase 3, Wegeners's autoantigen: From gene to antigen
20. Nuclear localization if the protein encodes by the Wilms tumor gene in embryonic and adult tissues
21. + hematopoietic progenitors during fetal development and early clonogenic growth
22. WT1 specific serum antibodies in patients with leukemia
23. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
24. Quantitation of antigen-reactive T cells in peripheral blood by IFN-γ-ELISPOT assay and chromium release assay: A four-centre comparative study
25. Flow cytometric determination of intracellular or secreted IFN-γ for quantitation of antigen-reactive T cells
26. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
27. - effector subset exerting ex-vivo tumor-specific cytolytic activity
28. Transendothelial migration of hematopoietic progenitor cells: Role of chemotactic factors
29. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
30. AT-cell clone's avidity is a function of its activation state
31. Leukemia blast-induced T cell anergy demonstrated by leukemia-derived dendritic cells in AML
32. T cell immunodeficiency following cytotoxic antineoplastic therapy: A review
33. + T-lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients
34. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines